Rising Demand for Relapsed Acute Myeloid Leukemia Drug Market Key Players, Growth Analysis during 2021-2027
The global relapsed acute myeloid leukemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Acute myeloid leukemia is a blood and bone marrow cancer with excess immature white blood cells. Additionally, relapsed acute myeloid leukemia occurs in patients who do not respond to the first line of treatment. The major factor accelerating the growth of the market is the increasing demand for better treatment options with minimal side effects.
Moreover, the market is also
growing due to the increasing prevalence of relapsed acute myeloid leukemia
globally. According to the Leukemia Care Organization UK, AML relapse affects
about 50% of all patients who achieved remission after initial treatment.
Additionally, it may occur several months to several years after treatment.
Further, almost all patient carries the risk of relapse with the majority of
relapses occurring within two to three years of initial treatment. Hence, the
rising rate of relapsed AML is in turn driving the growth of the market.
To Request a Sample of our Report on Relapsed Acute
Myeloid Leukemia Drug Market:
https://www.omrglobal.com/request-sample/relapsed-acute-myeloid-leukemia-drug-market
Some major players operating in the market include AbbVie
Inc., Amgen Inc., and Novartis Intetrnational AG, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in March 2020,
Gilead Sciences, Inc. announced that it will acquire Forty Seven, Inc. for $4.9
billion. The acquisition was aimed to strengthen Gilead’s immuno-oncology
research and development portfolio.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
AbbVie Inc., Amgen Inc., and Novartis Intetrnational AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Relapsed Acute Myeloid Leukemia Drug Market is Available @ https://www.omrglobal.com/industry-reports/relapsed-acute-myeloid-leukemia-drug-market
Global Relapsed Acute Myeloid Leukemia Drug Market Report
by Segment
By Type
• aNK Program
• AT-9283
• BI-836858
• Binimetinib
• BL-8040
• Others
By Application
• Clinic
• Hospital
• Others
Global Relapsed Acute Myeloid Leukemia Drug Market Report
by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert research
analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment